The development of novel chimeric antigen receptor gamma‐delta T cells against multiple myeloma and single‐cell RNA sequencing analysis
British Journal of Haematology · 2026
DOI: 10.1111/bjh.70660 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Yang Hong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Multiple Myeloma, Receptors, Chimeric Antigen, Receptors, Antigen, T-Cell, gamma-delta, Immunotherapy, Adoptive. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Key Research & Development Program of Jiangsu Province, Nanjing Drum Tower Hospital Youth Cultivation Fund.
Abstract (Originalsprache)
Chimeric antigen receptor (CAR) gamma‐delta (γδ) T cells offer a major histocompatibility complex‐independent, off‐the‐shelf alternative to conventional CAR alpha‐beta (αβ) Tcells, but their efficacy in multiple myeloma (MM) remains underexplored. In this work, we developed a series of novel CAR γδ T cells redirected to B‐cell maturation antigen (BCMA) and performed functional assays compared to CAR αβ T cells. As a result, novel CAR γδ T cells demonstrated similar activation upon antigen stimulation compared with CAR αβ T cells but showed lower proliferative capacity and less durable cytotoxicity. In vivo, higher doses of CAR γδ T cells were required to achieve tumour control comparable to CAR αβ T cells. Among CAR constructs, those with cluster of differentiation 3 (CD3ε or CD3ζ) intracellular domain exhibited superior cytotoxicity and in vivo efficacy. Single‐cell transcriptomic profiling revealed the low ratio of cycling CAR γδ T cells after antigen stimulation limited the persistence of CAR γδ T cells. In conclusion, our developed novel CAR γδ T cells effectively eliminated MM cells in vitro, but exhibited limited in vivo persistence compared to traditional CAR αβT cells. These findings establish a baseline for utilizing γδ T cells as an off‐the‐shelf platform and highlight that addressing the proliferation bottleneck through further engineering is essential for future clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Department of Hematology, Nanjing Drum Tower Hospital, Clinical College of Nanjing University of Chinese Medicine, Nanjing, China.
- Isao Biotherapeutics Co. Ltd., Nanjing, Jiangsu, China.
ORCID-Profile: Bing Chen
Förderung
- National Natural Science Foundation of China
- Key Research & Development Program of Jiangsu Province
- Nanjing Drum Tower Hospital Youth Cultivation Fund
- the Natural Science Foundation of Jiangsu Province
Zitieren
APA
Hong, Y., Zhang, C., Wang, J., Zhang, J., Zhu, Y., Zhang, Y., Shao, B., Yang, Y., Tan, T., Xu, P., & Chen, B. (2026). The development of novel chimeric antigen receptor gamma‐delta T cells against multiple myeloma and single‐cell RNA sequencing analysis. British Journal of Haematology. https://doi.org/10.1111/bjh.70660
Vancouver
Hong Y, Zhang C, Wang J, Zhang J, Zhu Y, Zhang Y, et al. The development of novel chimeric antigen receptor gamma‐delta T cells against multiple myeloma and single‐cell RNA sequencing analysis. British Journal of Haematology. 2026. doi:10.1111/bjh.70660
BibTeX
@article{Hong2026,
author = {Hong, Yang and Zhang, Cuiling and Wang, Jue and Zhang, Jianhua and Zhu, Yuanyuan and Zhang, Yage and Shao, Bang and Yang, Yongkun and Tan, Taochao and Xu, Peipei and Chen, Bing},
title = {The development of novel chimeric antigen receptor gamma‐delta T cells against multiple myeloma and single‐cell RNA sequencing analysis},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70660}
}
EUVIMED